An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Must have previously treated metastatic colorectal cancer

- Must have RAS mutation and microsatellite stability status results as part of medical
history

- Must agree to provide archival or newly obtained tumor tissue sample prior to the
start of treatment in this study

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

- Ability to swallow pills or capsules

- Adequate organ functions

- Ability to comply with study visits, treatment, procedures, PK and PD sample
collection, and required study follow-up

Exclusion Criteria:

- BRAF V600 mutant colorectal cancer

- Active brain metastases or leptomeningeal metastases

- Active, known or suspected autoimmune disease

- Histology other than adenocarcinoma

- Participants with a condition requiring systemic treatment with either corticosteroids
(> 10 mg daily prednisone equivalents) or other immunosuppressive medications within
14 days of study treatment administration

- History of interstitial lung disease or pneumonitis

- Prior treatment with immune checkpoint inhibitors and MEK inhibitors

- History of allergy to study treatments or any of its components of the study arm that
participant is enrolling

Other protocol defined inclusion/exclusion criteria could apply